Grace Therapeutics, Inc. Lease, Cost
Grace Therapeutics, Inc. (GRCE) reported Lease, Cost of $0 for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2024-11-13
- Grace Therapeutics, Inc. lease, cost for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Grace Therapeutics, Inc. lease, cost for the quarter ending 2023-09-30 was $23.00K.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month |
|---|---|---|
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 |
| 2023-09-30 | $23.00K 10-Q · filed 2024-11-13 | $47.00K 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |